Ysios news
18.09.20
LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs
15.09.20
ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio
portfolio news
24.09.20
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
18.09.20
LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs
